De Novo Nucleotide Biosynthesis: How Cells Build Purines and Pyrimidines From Scratch

Every time a cell divides, it needs enough new DNA and RNA building blocks to duplicate its entire genome. Nucleotides do far more than spell out genetic sequences, though — they’re the energy currency of the cell (ATP, GTP), pieces of essential cofactors (NAD, FAD, coenzyme A), activated carriers in biosynthesis (UDP-glucose, CDP-diacylglycerol), and signaling molecules in their own right (cAMP, cGMP). Cells make them two ways: de novo synthesis, which builds nucleotides from simple metabolic precursors, and salvage pathways, which recycle bases and nucleosides released as nucleic acids break down. This guide focuses on the de novo route — the tightly regulated chemistry that builds purine and pyrimidine rings out of amino acids, carbon dioxide, and a couple of carrier molecules.

What Is De Novo Nucleotide Synthesis?

De novo — “from scratch” — synthesis builds nucleotides from simple precursors: amino acids, ribose 5-phosphate, CO2, and ammonia, rather than by recovering intact bases. That distinction matters more than it first appears. Even though free bases such as adenine, guanine, cytosine, and uracil exist inside cells, they are not intermediates in the de novo pathways. Purine and pyrimidine rings are built atom by atom, or as small pre-assembled pieces, and only afterward take their place as finished nucleotides — and the two ring systems go about this in almost opposite ways.

Despite building chemically distinct rings, purine and pyrimidine synthesis share several key ingredients. Phosphoribosyl pyrophosphate (PRPP) supplies the ribose-phosphate unit for both, and in both pathways that ribose is retained intact in the final product. Each pathway also leans on a specific amino acid as core building material: glycine is incorporated whole into the purine ring, while aspartate contributes much of the pyrimidine ring. Glutamine is the workhorse nitrogen donor throughout, handing off its amide nitrogen at five separate steps across the two pathways combined.

These pathways aren’t run casually. In the purine pathway especially, the biosynthetic enzymes appear to associate into large multienzyme complexes, letting intermediates pass from one active site to the next without diffusing freely through the cytoplasm. That efficiency matters because cellular nucleotide pools are surprisingly small — typically around 1% or less of what’s needed to complete a full round of DNA replication. Cells can’t stockpile nucleotides; they have to keep synthesizing them throughout replication and transcription, which is exactly why enzymes in these pathways are such effective targets for chemotherapy and antimicrobial drugs.

How Purine Nucleotides Are Built

Purines are constructed directly on top of the ribose-phosphate scaffold — the ring is built piece by piece while already attached to PRPP. The pathway was worked out in detail by John Buchanan and G. Robert Greenberg in the 1950s, and it runs through eleven enzyme-catalyzed steps to produce the first complete purine nucleotide.

1. Glutamine primes PRPP. Glutamine donates its amide nitrogen to C-1 of PRPP, producing 5-phosphoribosylamine — an intermediate so reactive it has a half-life of only about 30 seconds at physiological pH.
2. Glycine is added whole. ATP first activates glycine’s carboxyl group as an acyl phosphate to drive the condensation, contributing three of the ring’s future atoms.
3. A formyl group is added. The glycine-derived amino group is formylated using N10-formyltetrahydrofolate as the one-carbon donor.
4. A second nitrogen arrives. Glutamine donates another amide nitrogen.
5. The first ring closes. Dehydration closes the five-membered imidazole ring, producing 5-aminoimidazole ribonucleotide (AIR).
6. A carboxyl group is added. Unusually for a biological carboxylation, this step draws directly on bicarbonate and needs no biotin.
7. A rearrangement shifts the carboxylate to a different position on the ring.
8. Aspartate contributes its amino group across two reactions — first forming an amide bond, then releasing the rest of the aspartate skeleton as fumarate.
9. A final carbon arrives, again from N10-formyltetrahydrofolate.
10. The second ring closes, fusing a six-membered ring onto the imidazole ring.
11. Inosinate (IMP) is complete — the first fully formed purine nucleotide, and the branch point for everything downstream.

From IMP, the pathway branches. Converting IMP to adenylate (AMP) adds an amino group from aspartate, using GTP — not ATP — as the energy source for the key intermediate step. Converting IMP to guanylate (GMP) instead proceeds through an NAD+-dependent oxidation at C-2, followed by an amino group from glutamine, with ATP cleaved to AMP and pyrophosphate in the final step. This asymmetry — GTP driving AMP synthesis, ATP driving GMP synthesis — turns out to be central to how cells keep the two nucleotides in balance, as the regulation section below explains.

How Pyrimidine Nucleotides Are Built

Pyrimidine synthesis takes the opposite strategy from purine synthesis: the six-membered ring is built first, as a free-standing molecule, and only afterward attached to ribose phosphate.

1. Carbamoyl phosphate meets aspartate. Carbamoyl phosphate — also an intermediate in the urea cycle — reacts with aspartate to form N-carbamoylaspartate. This is the pathway’s first committed step, catalyzed by aspartate transcarbamoylase (ATCase).
2. The ring closes. Water is removed, producing L-dihydroorotate.
3. Dihydroorotate is oxidized to orotate, with NAD+ serving as the electron acceptor.
4. Ribose finally enters the picture. PRPP donates its ribose-phosphate group to orotate, producing orotidylate.
5. Decarboxylation yields uridylate (UMP) — the first true pyrimidine ribonucleotide.
6. UMP is phosphorylated, through two kinase reactions, to UTP.
7. CTP is formed from UTP by cytidylate synthetase, which consumes one ATP and typically draws its nitrogen from glutamine — though in some organisms the enzyme can use free ammonia directly.

Keeping Supply and Demand Balanced: Regulation

Purine Regulation

Purine synthesis is controlled by three cooperating feedback mechanisms, tuned to balance total purine output against the specific need for adenylate versus guanylate.

• Early control: the first reaction unique to purine synthesis — glutamine-PRPP amidotransferase converting PRPP to 5-phosphoribosylamine — is inhibited by the pathway’s own end products, IMP, AMP, and GMP. AMP and GMP act together here, producing a stronger, synergistic brake than either alone.
• Branch-point control: further down the pathway, excess GMP selectively inhibits IMP dehydrogenase without touching AMP production, while excess adenylate selectively inhibits adenylosuccinate synthetase without touching GMP production. If both accumulate at once, IMP itself builds up and inhibits an earlier step — a pattern called sequential feedback inhibition.
• Reciprocal substrate use: converting IMP to AMP requires GTP, while converting IMP to GMP requires ATP. This cross-wiring means an abundance of one nucleotide triphosphate preferentially fuels production of the other, keeping the two pools balanced.
• Upstream control: even PRPP production is regulated — ribose phosphate pyrophosphokinase (PRPP synthetase) is inhibited allosterically by ADP and GDP, along with other metabolites for which PRPP is a starting material.

Pyrimidine Regulation

Pyrimidine synthesis is controlled mainly at its first committed step, aspartate transcarbamoylase, which is inhibited by the pathway’s end product, CTP. In bacteria, ATCase is a classic textbook example of allosteric regulation in action: the enzyme assembles from six catalytic and six regulatory subunits. The catalytic subunits bind substrate; the regulatory subunits bind CTP. When CTP is absent, the whole complex sits in a high-activity conformation. As CTP accumulates and binds the regulatory subunits, it triggers a conformational shift that’s transmitted to the catalytic subunits, switching the enzyme to a low-activity state. ATP opposes this shift — so the balance between ATP and CTP binding effectively lets the enzyme sense the cell’s purine and pyrimidine supplies against each other.

Why De Novo Synthesis Matters

Because cells can’t stockpile more than a fraction of the nucleotides they need at any moment, keeping de novo synthesis running smoothly is essential for both DNA replication and RNA transcription — and disruptions in these pathways have outsized medical consequences.

At the far end of the purine pathway, nucleotides are eventually broken down to uric acid. When the salvage enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) is absent or nearly absent — a genetic condition called Lesch-Nyhan disease — cells fail to recycle purine bases, lean more heavily on de novo synthesis, and drive uric acid production sharply upward. The resulting hyperuricemia can cause gout-like joint disease alongside a distinctive neurological and behavioral syndrome. A milder, far more common version of the same underlying chemistry — excess uric acid crystallizing in the joints — is simply known as gout, and doesn’t require a genetic salvage defect to occur.

The flip side of this is deliberately medical: because rapidly dividing cells depend so heavily on nucleotide synthesis, enzymes in these pathways are prime drug targets. Blocking a step in purine or pyrimidine biosynthesis slows replication specifically in the fastest-growing cells, a principle behind a range of drugs used against cancer, autoimmune disease, and infection.

Frequently Asked Questions

References and Further Reading